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Background and Aims: We aimed to evaluate the expression of HER2 marker in dif-
ferentiated thyroid cancers and its correlation with tumor size and stage.
Materials and Methods: This is a cross-sectional study that was performed at Tehran 
Shohada-E-Tajrish hospital from 2015 to 2019. Patients with differentiated thyroid can-
cer were enrolled in the study. Patients’ baseline characteristics and tumor properties 
were recorded. Expression of tumor marker testing was conducted with IHC. Analysis 
was performed with SPSS version 20.
Results: Fifty cases of thyroid cancer with a mean age of 46.6 years (78% females) 
were evaluated. 86% of cases were PTC, 10% FTC, and 4% hurthle cell carcinoma. 
HER2 positivity rate was 34% totally. HER2 positivity in FTC and PTC patients was 
40% and 34.9%, respectively. 84% of patients had a sporadic tumor. HER2 positivity 
rate in sporadic tumors was 28.6% and 62.5% in familial cases (p=0.063). HER2 status 
did not association with clinicopathologic factors, significantly.
Conclusion: With the findings of our study, HER2 can’t be considered a prognostic 
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INTRODUCTION
Thyroid cancer is the greatest prevalent endocrine system 
cancer. Medullary, anaplastic, and differentiated including 
papillary, follicular, and hurtle are the three major histo-
logic forms.[1-3]  Ionizing radiation exposures and a few 
rare familial syndromes are among the few known risk fac-
tors for thyroid cancer. Thyroid cancer is more common in 
women, according to epidemiological findings.[4, 5] The 
fact that thyroid cancer is more common in women during 
their menstrual years indicates that estrogen and progester-
one may play important roles in thyroid cancer pathogen-
esis. Thyroid cancer risk was found to be lower in women 
after menopause. [6, 7] Several human epithelial tumors, 
including breast, ovarian, gastric, and colorectal cancers, 
have the human epidermal growth factor receptor 2 (HER2) 
gene enhanced and the protein overexpressed. [8-10] Over-
expression and amplification of HER2 have been related 
to a poor outcome and a poorly differentiated phenotype in 
these tumors. [8, 11] The HER2 is of special interest in tu-
mor biology since it is both a powerful predictive factor in 
a variety of tumor types and a very useful therapeutic target 
in breast and stomach cancer. There isn’t enough evidence 
to determine that HER2 has an effect in thyroid cancer. 
In some studies it was observed that in involving thyroid 
patients, reported HER2 overexpression rates range from 
0% to 79.5 percent. [12-16] In the recent literature, there 
is very little general agreement on this marker’s possible 
prognostic and therapeutic importance in thyroid cancer.
[17, 18] Due to there is a low consensus about the effect of 
HER2 on thyroid cancer and its relationship with size and 
stage of tumors, in this study, we aimed to investigate the 
expression of HER2 surface protein in differentiated thy-
roid cancer and evaluation of its relationship with stage and 
size of tumors.
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(30%) stage II. In terms of tumor invasion depth (T), 33 
cases (66%) were T1, 11 cases (22%) were T2, and 6 cases 
(12%) were T3. In terms of lymph node involvement, 39 
patients (78%) did not have lymph node involvement and 
11 patients (22%) had lymph node involvement.
The patient’s gender composition was measured by HER-2 
status. In females, 25 patients (64.1%) were negative and 
14 patients (35.9%) were positive for HER2. Among males, 
8 cases (72.7%) were negative and 3 cases (27.3%) were 
positive for HER2 (p = 0.594 -based on chi square.) The age 
of patients in the HER2 positive group was 45.88 ± 16.73 
years and in the HER-2 negative group was 47.06 ± 12.57 
years (p = 0.780). There was no statistically significant dif-
ference between HER2 positive and negative groups in the 
terms of age and sex.
In follicular thyroid carcinoma cases, 3 patients were HER2 
negative (60%) and 2 patients were HER2 positive (40%). 
In Hurthle cell cases, 2 patients (100%) were HER2 nega-
tive. In PTC cases, 28 patients (65.1%) were HER2 nega-
tive and 15 patients (34.9%) were HER2 positive (p = 0.570 
-based on chi square). 
Between sporadic cases, 30 patients (71.4%) were HER2 
negative and 12 patients (28.6%) were HER2 positive and in 
familial cases, 3 patients (37.3%) were HER2 negative and 
5 patients (62.5%) were HER2 positive (p = 0.063-based on 
chi square).
The mean tumor size in the HER2 positive group was 2.63 
± 2.49 cm and in the HER2 negative group was 2.16 ± 2.26 
cm (p = 0.509). In terms of disease stage, in stage-1 cas-
es, 23 patients (65.7%) were HER2 negative and 12 pa-
tients (34.3%) were HER2 positive. In stage-2, 10 patients 
(66.7%) were HER2 negative and 5 patients (33.3%) were 
HER2 positive (p = 0.948-based on chi square). 
In T1 cases, 24 patients (72.7%) were HER2 negative and 
9 patients (27.3%) were HER2 positive. In T2 cases, 5 pa-
tients (45.5%) were HER2 negative and 6 patients (54.5%) 
were HER2 positive. In T3 cases, 4 patients (66.7%) were 
HER2 negative and 2 patients (33.3%) were HER2 positive 
(p = 0.255-based on chi square). In cases with N0, 27 pa-
tients (69.2%) were HER2 negative and 12 patients (30.8%) 
were HER2 positive. In N1 cases, 6 patients (54.5%) were 
HER2 negative and 5 patients (45.5%) were HER2 positive 
(p = 0.364-based on chi square). 
In the following, we have analyzed the parameters based 
on the histological type of cancer and due to the very small 
number of Hurthle cases, we excluded them from the anal-
ysis. 
The gender compositions were: in follicular cases, 4 pa-
tients were female (80%) and 1 was male (20%) and in the 
PTC cases, 33 patients (76.7%) were female and 10 patients 
(23.3%) were male (p = 0.735-based on chi square). The 
patient’s age in the follicular group was 45.20 ±12.93 years 
and in the PTC group was 47.11 ±14.43 years (p = 0.778- 
based on Mann-Whitney U-test). In the follicular group, all 
cases (100%) were sporadic, and in the PTC group, 36 cas-
es were sporadic (83.7%) and 7 cases (16.3%) were familial 
MATERIALS and METHODS
This study was approved by ethical committee of medical 
university of Shahid Beheshti and it took ethical code from 
this committee (IR.SBMU.MSP.REC.1398.870). In this de-
scriptive cross-sectional study, patients who were referred 
to Shohada-e-Tajrish Hospital (Tehran-Iran) for thyroid 
cancer surgery from 2015 to 2018 with thyroid cancers, 
were studied. All patients in this duration were studied. The 
inclusion criterion was having differentiated thyroid cancer 
and exclusion criteria were patients with other concomitant 
malignancies, patients who did not consent to study, pa-
tients whose samples were not available for HER2 testing, 
and undifferentiated cancers in pathology. Five hundred 
and fifty-eight patients were evaluated and finally, 50 pa-
tients were enrolled in the study according to inclusion and 
exclusion criteria. 
Written informed consent was obtained from all patients 
to participate in the study and no costs were imposed on 
patients. Patient’s data including age, sex, and family his-
tory were asked from them. Tumor characteristics includ-
ing pathology type, tumor size, tumor invasion status were 
determined by preoperative and postoperative pathological 
examination and evaluation of surface protein expression. 
HER2 tumor cells were analyzed by IHC. All histopatho-
logic specimens were studied by a specific expert patholo-
gist during the study.
Follow-ups of patients (one week, six months, and one 
year after surgery) were performed over time, and recovery 
status, recurrence, or mortality was recorded. Whole-exon 
mutation data were extracted from the Thyroid Cancer Ge-
nomic Data Analysis Center (GDAC) for genetic analysis. 
HER2-related information was obtained from this center 
and their mutations were assessed in patient samples.
Statistical analysis 
SPSS software version 20 was used for data analysis. Ab-
solute and relative abundance of markers was reported in 
the subgroups. In non-parametric data, the Mann-Whitney 
U test was used to compare patients age and tumor size 
between groups and used Chi-square test to compare dif-
ference between percent’s in each categorical factors. Sta-
tistically significant limit (p-value) was considered lower 
than 0.05.
RESULTS
In this study, 50 differentiated thyroid cancers were stud-
ied with a mean age of 46.60 ± 13.96 years. Thirty-nine 
patients were female (78%) and 11 (22%) were male. His-
tologically, 5 cases (10%) had follicular thyroid carcinoma, 
2 cases (4%) had hurthle cell cancer and 43 cases (86%) 
had papillary thyroid carcinoma. The HER2 marker was 
negative in 33 cases (66%) and overexpressed in 17 cas-
es (34%). In terms of family distribution pattern, 42 cases 
(84%) had a sporadic pattern and 8 cases (16%) had cancer 
with a familial distribution pattern. The mean of the largest 
tumor diameters in this study was 2.32 ± 2.33 cm. In terms 
of staging, 35 patients (70%) had stage I and 15 patients 
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(p = 0.262- based on chi square). Tumor size in the follic-
ular group was 5.70 ± 3.09 cm and in the PTC group was 
1.89 ± 1.95 cm (p <0.001- based on Mann-Whitney U-test). 
In terms of disease stage, in the follicular group, 2 patients 
(40%) were in stage 1 and 3 patients (60%) were in stage 2. 
In PTC cases, 31 patients (72.1%) were in stage 1 and 12 
patients (27.9%) were in stage 2 (p = 0.213- based on chi 
square).
In terms of tumor invasion depth,  in the follicular group, 
3 cases (60%) were T2 and 2 cases (40%) were T3. In the 
PTC group, 32 cases (74.4%) were in T1 stage, 7 patients 
(16.3%) were in T2 stage and 4 patients (9.3%) were in T3 
stage (p = 0.016- based on chi square). 
In terms of lymph node involvement in the follicular group, 
N0 in 4 patients (80%) and N1 in 1 patient (20%) were seen. 
In the case of PTC, 33 patients (76.7%) were N0 and 10 pa-
tients (23.3%) were N1 (p = 0.735- based on chi square).
The status of the parameters was analyzed based on the spo-
radic/familial distribution of the tumors. Among females, 
32 cases (82.1%) were sporadic and 7 cases (17.9%) were 
familial and in the males, 10 cases (90.9%) were sporadic 
and 1 case (9.1%) was familial (p = 0.479- based on chi 
square). the mean patient’s age was 45.61± 13.70 years in 
sporadic cases and 52.12 ± 14.98 years in familial cases 
(p = 0.231). Tumor size in sporadic cases was 2.17 ± 2.38 
cm and in familial cases was 3.15 ± 1.94 cm (p = 0.281). 
About staging, in sporadic cases, tumor stages were stage 
1 in 30 cases (71.4%) and stage 2 in 12 cases (28.6%) and 
in familial cases, in 5 cases (62.5%) were in the stage 1 and 
3 cases (37.5%) were in the stage 2 (p = 0.614- based on 
chi square). About the depth of tumor invasion in sporadic 
cases, 31 cases were (73.8%) T1, 7 cases (16.7%) were T2 
and in 4 cases (9.5%) were T3 and in familial cases, 2 cases 
(25%) were T1, 4 cases (50%) were T2 and 2 cases (25%) 
were T3 (p = 0.028- based on chi square). 
 In sporadic cases, 33 cases (78.6%) were N0 and 9 cases 
(21.4%) were N1 and in familial cases, 6 cases (75%) were 
N0 and 2 cases (25%) were N1 (p = 0.823- based on chi 
square).
There was no mortality in all patients during the study.
DISCUSSION
In the current study that was performed on 50 patients with 
thyroid cancers including PTC, FTC, and hurthle cell, 78% 
were female and 22% were male. About subtypes of carci-
nomas, FTC in 10%, hurthle cell in 4%, and PTC in 86% 
was seen. HER2 was negative in 33 cases (66%) and over-
expressed in 17 cases (34%), overall. In the Ruggeri et al 
study, it was found HER2 overexpression was discovered 
in 20/45 (44%) FTC and 8/45 (18%) PTC, and it had a sig-
nificant difference. We found that HER2 was positive in 
40% of cases with FTC. In PTC cases, HER2 was positive 
in 34.9% of cases. Our findings were similar to Ruggeri 
et al study, approximately. In fact, about the relationship 
between FTC and HER2, these findings were similar but 
about HER2 relationship with PTC, there was a contrast 
between these two studies. This difference may be com-
ing from the understudy population because, in the present 
study, 50 patients were studied but in the Ruggeri et al study, 
it was 90 patients.[19]
In the Dai et al study, it was demonstrated that there was 
a significant correlation between HER2 and PTC. In fact, 
there was a positive correlation between HER2 and PTC, and 
overexpression of HER2 can increase the risk of PTC occur-
rence. In the present study, we observed HER2 positive cells 
were seen in about 35% of patients with PTC. We saw HER2 
had more correlation with FTC. In the Dai et al study HER2 
relationship with FTC did not assess. About the relationship 
between PTC andHER2, it seems these studies are similar.
[20]
In the Wei et al study, it was concluded that HER2 is a po-
tential biomarker for anaplastic thyroid cancer. In the current 
study, we found that HER2 could be found in PTC and MTC 
but we didn’t evaluate this relation with anaplastic thyroid 
cancer.[21] 
In the Kavanagh et al study it was found that HER2 was as-
sociated with poorly differentiated tumors, tumor invasion, 
and disease relapse. In the current study, although we ob-
served invasion mount of HER2 positive carcinomas were 
not statistically significant and HER2 negative carcinomas 
had a higher amount of invasion than HER2 positive, HER2 
positive carcinomas had considerable rates of invasion, and 
some studies should be performed in the future. Also, in the 
present study, 34.3% of HER2 positive carcinomas were 
stage1, 33.3% of them were in stage2 and all of them didn’t 
have a statistically significant difference. In fact, HER2 did 
not correlate with types of differentiation. These studies are 
different in findings . [22]
In the Zhang et al study, it was found that there was a sig-
nificant relationship between differentiated thyroid carcino-
mas size and mortality, especially about PTC. Higher tumor 
size had a higher hazard ratio for mortality. In the current 
study, we saw there was no relation between mortality rate 
and size of tumors and follicular type had higher size than 
PTC. These findings are very different. One of the reasons 
for this difference could be the difference in follow-up dura-
tion in the two studies. In the current study, all patients were 
followed up for one year but in the Zhang et al study, it was 
about 2 years. This could be the cause of mortality in Zhang 
et al study. Also, in the Zhang et al study, all patients were in 
stage4 for differentiated carcinomas and it could be another 
reason for the difference. In the current study, FTCs had a 
higher size than PTCs and it was another difference between 
these studies. [23]
In our study, the sporadic or familial distribution of thyroid 
cancer in HER2 positive patients in 28.6% of cases, and in 
62.5% of cases it was familial, but this difference was not 
significant. A study by Caria et al found a significant rela-
tionship of HER2 with familial type in PTC. These findings 
in these two studies were different. Also, these studies were 
different in terms of method of study because our study was 
performed on all differentiated thyroid cancer but Caria et al 
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study was performed on PTC. [24] In the Jiwang et al study 
it was mentioned that there was a significant relationship 
between T and N stage between the familial and sporadic 
PTC. These findings were approximately similar to our re-
sults because in the current study we found that higher spo-
radic pattern in PTC but this difference was not statistically 
significant [25].
CONCLUSION
There is no significant difference between age, sex, type 
on differentiated thyroid cancer, sporadic/familial type, 
TMN scoring with HER2 positivity or negativity. Also, be-
tween PTC and FTC there were no statistically significant 
differences in sex, age, familial/sporadic type, staging, and 
lymph node involvement. But there were significant differ-
ences between FTC and PTC in terms of size and depth of 
tumor invasion of the tumor. Overall, there was a signifi-
cant difference between the depth of tumor invasion in the 
sporadic and familial types of tumors. 
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